Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448512 | 0.95 | ALDH1A1 (0.37) | USP2ALDH1A1HPGDTDP1 | |
| SCHEMBL446626 | 0.80 | POLB (0.32) | USP2ALDH1A1HPGDTDP1 | |
| SCHEMBL2096586 | 0.78 | MAPT (0.34) | USP2ALDH1A1HPGDTDP1 | |
| SCHEMBL2096513 | 0.77 | ALDH1A1 (0.37) | USP2ALDH1A1HPGDTDP1 | |
| SCHEMBL27645167 | 0.76 | USP2 (0.31) | USP2ALDH1A1HPGDTDP1 | |
| SCHEMBL2094790 | 0.75 | ALDH1A1 (0.34) | USP2ALDH1A1HPGDTDP1 | |
| SCHEMBL27666122 | 0.75 | ALDH1A1 (0.33) | USP2ALDH1A1HPGDTDP1 | |
| SCHEMBL2095889 | 0.74 | OPRM1 (0.38) | ALDH1A1HPGDTDP1 | |
| SCHEMBL2091925 | 0.72 | — | — | |
| SCHEMBL2095737 | 0.71 | KDM4E (0.37) | USP2ALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | USP2 3755/4885ALDH1A1 461/4885HPGD 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.